Discounted for Defensive Growth Limits
Abbott trades at a discount because its growth lags the most dynamic peers. Revenue is strong, but EPS guidance is diluted by recent acquisitions. The market sees a defensive healthcare name, not a growth leader. For a higher valuation, organic growth needs to accelerate.
Published by AssetNext · 2026-06-05
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-06-04 | Gap to peers | 45 | -32.9% | -2.9% |
| 2026-06-03 | Gap to peers | 46 | -35.7% | -4.3% |
| 2026-05-26 | Gap to peers | 47 | -35.9% | -4.6% |
| 2026-05-26 | Gap to peers | 46 | -35.9% | -2.4% |
| 2026-05-22 | Gap to peers | 45 | -35.4% | -0.4% |
Break down ABT's structural position across all peer dimensions with the interactive app.